Crypto markets often pause before capital shifts direction. When Bitcoin slows near key levels, attention usually sta ...
Nektar Therapeutics has two Phase IIb studies underway for rezpeg in atopic dermatitis and severe alopecia areata, with read-outs expected in 1H'25. Success in either indication would significantly ...
SSC Phase 13 Answer Key 2025 : SSC Selection Post Answer Key 2025 is likely to be released soon by the Staff Selection Commission. The SSC Selection Post Phase 13 Answer Key 2025 which is generally ...
Cytokinetics' share price surged on rumors of potential takeover interest from Novartis and AstraZeneca. The buyout of Myokardia shows how attractive an asset like aficamten can be, but the price tag ...
Phase 2 on the roadmap focuses on core protocol readiness. This includes finalizing smart contracts, preparing liquidity ...
The U.S. Air Force's two experimental F-15EX Eagle II fighters return from a test mission over the Gulf of Mexico on Aug. 2, 2023. (Tech. Sgt. John McRell/U.S. Air Force) WASHINGTON — The U.S. Air ...
PERTH AMBOY — The second phase of a massive three-phase project to rebuild NJ Transit's Raritan River Bridge began on a sweltering Tuesday, June 24. "So many of the coastal towns, of which I live in ...
GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...
− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, ...
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary ...